<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03716076</url>
  </required_header>
  <id_info>
    <org_study_id>H18-02232</org_study_id>
    <nct_id>NCT03716076</nct_id>
  </id_info>
  <brief_title>Carbetocin on Myocardial Repolarization Dynamics in Obstetrics Study</brief_title>
  <acronym>CaRDIO</acronym>
  <official_title>The Effect of Carbetocin Dose on Dispersion of Myocardial Repolarization in Healthy Parturients Scheduled for Elective Cesarean Delivery Under Spinal Anesthesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Relationship between carbetocin dose on transmural dispersion of repolarization (TDR).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carbetocin is a uterotonic used to prevent postpartum hemorrhage. Although it has been proven
      to be completely safe, little is known about its effects on the electrical activity of the
      heart. The investigators aim to determine its effect on myocardial repolarization dynamics
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac repolarization dynamics</measure>
    <time_frame>5 minutes post-carbetocin administration</time_frame>
    <description>cardiac repolarization indices on ECG - QTc interval</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Arrythmias</condition>
  <arm_group>
    <arm_group_label>C50</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participant receives 50 mcg of carbetocin post-delivery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C100</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participant receives 100 mcg of carbetocin post-delivery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbetocin</intervention_name>
    <description>50 mcg or 100 mcg bolus of carbetocin</description>
    <arm_group_label>C100</arm_group_label>
    <arm_group_label>C50</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant patients ≥ 36 weeks gestation, for elective Cesarean delivery under neuraxial
             anesthesia

          -  American Society of Anesthesiologists (ASA) class 2

          -  Patients ≥ 19 years of age

        Exclusion Criteria:

          -  Long QT syndrome

          -  Cardiac disease or rhythm abnormalities

          -  Family history of long QT syndrome or abnormal cardiac conduction

          -  Currently taking medication that is known to prolong the QT interval

          -  Women who are high risk for uterine atony as outlined in SOGC

          -  Known allergic reaction or hypersensitivity to Carbetocin or any other oxytocin
             homologue

          -  Patients who are unable to give informed consent because of a language barrier as the
             study team only speaks English and will be unable to complete consent process and
             study procedure appropriately.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anton Chau, MD MMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James D Taylor, BSc</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>6076</phone_ext>
    <email>james.taylor1@phsa.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natasha G Clunies-Ross, BSc MBBS</last_name>
    <phone>604-875-2424</phone>
    <phone_ext>6076</phone_ext>
    <email>natasha.cluniesross@cw.bc.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BC Women's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James D Taylor, BSc</last_name>
      <phone>604-875-2424</phone>
      <phone_ext>6076</phone_ext>
      <email>james.taylor1@phsa.ca</email>
    </contact>
    <contact_backup>
      <last_name>Natasha G Clunies-Ross, MBBS FRCA</last_name>
      <phone>604-875-2424</phone>
      <phone_ext>6076</phone_ext>
      <email>natasha.cluniesross@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Anton Chau, MD MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Natasha Clunies-Ross, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Roston, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Taylor, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simon Whyte, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Gorges, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arianne Albert, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giselle Villar, MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Anton Chau</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Carbetocin</keyword>
  <keyword>Myocardial repolarization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carbetocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

